Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiovascular risk, and increases adiponectin levels. Weight gain correlates with health improvement.
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed.
Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days.